MOLECULAR MARKERS OF ENDOGENOUS NEUROPROTECTION IN THE BRAIN OF RATS WITH EXPERIMENTAL PARKINSON'S DISEASE AND ON THE BACKGROUND OF USING NEW PHARMACOTHERAPY SCHEMES
Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly.
The aim of the study. To study apoptotic processes and their role in the formation of dopaminergic neurodegeneration and to develop new treatment regimens with a specific neuroprotective effect on the dopaminergic system.
Materials and methods. The study was carried out on 90 Wistar rats at the age of 6 months weighing 220–290 grams. Parkinsonism was induced by the administration of the neurotoxin MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to experimental rats with neuroprotective treatment: I – Intact (passive control); II – animals with experimental Parkinson's disease (PD, active control); III – PD + Amantadine (AM) IV – PD + AM + Cerebrocurin; V – PD + AM + Pramistar; VI – PD + AM + Gliatilin; VII – PD + AM + Noofen; VIII – PD + AM + Pronoran; IX – PD + AM + Melatonin.
Results. The obtained data indicate that neuroprotective therapy of PD with drugs such as melatonin, cerebrocurin, pronoran and gliatilin in combination with amantadine leads to an increase in the expression of the HIF-1α, HIF-3α, HSP70 genes, bcl-2 proteins and decrease c-fos proteins with caspase-3 as markers of apoptosis and can also serve as a molecular marker for the activation of endogenous neuroprotection mechanisms under the conditions of an experimental PD.
Conclusions. The study experimentally demonstrated a new target of neuroprotection in PD conditions – apoptosis of dopamine-producing neurons and substantiated modulators of this process – drugs for combined therapy with amantadine (melatonin, cerebrocurin, pronoran and gliatilin) as promising drugs for the treatment of PD.
Erekat, N. S. (2018). Apoptosis and its Role in Parkinson’s Disease. Parkinson’s Disease: Pathogenesis and Clinical Aspects, 65–82. doi: https://doi.org/10.15586/codonpublications.parkinsonsdisease.2018.ch4
Sadlon, A., Takousis, P., Alexopoulos, P., Evangelou, E., Prokopenko, I., Perneczky, R. (2019). miRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases. Trends in Molecular Medicine, 25 (8), 662–672. doi: https://doi.org/10.1016/j.molmed.2019.05.006
Yuan, J., Amin, P., Ofengeim, D. (2018). Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nature Reviews Neuroscience, 20 (1), 19–33. doi: https://doi.org/10.1038/s41583-018-0093-1
Gelders, G., Baekelandt, V., Van der Perren, A. (2018). Linking Neuroinflammation and Neurodegeneration in Parkinson’s Disease. Journal of Immunology Research, 2018, 1–12. doi: https://doi.org/10.1155/2018/4784268
Larsen, S. B., Hanss, Z., Krüger, R. (2018). The genetic architecture of mitochondrial dysfunction in Parkinson’s disease. Cell and Tissue Research, 373 (1), 21–37. doi: https://doi.org/10.1007/s00441-017-2768-8
Jiang, P., Dickson, D. W. (2017). Parkinson’s disease: experimental models and reality. Acta Neuropathologica, 135 (1), 13–32. doi: https://doi.org/10.1007/s00401-017-1788-5
Bohush, A., Niewiadomska, G., Filipek, A. (2018). Role of Mitogen Activated Protein Kinase Signaling in Parkinson’s Disease. International Journal of Molecular Sciences, 19 (10), 2973. doi: https://doi.org/10.3390/ijms19102973
Horvath, I., Iashchishyn, I. A., Moskalenko, R. A., Wang, C., Wärmländer, S. K. T. S., Wallin, C. et. al. (2018). Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson’s disease: ex vivo and in vitro studies. Journal of Neuroinflammation, 15 (1). doi: https://doi.org/10.1186/s12974-018-1210-9
Ma, C., Pan, Y., Yang, Z., Meng, Z., Sun, R., Wang, T. et. al. (2016). Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats. Life Sciences, 144, 113–120. doi: https://doi.org/10.1016/j.lfs.2015.11.019
Belenichev, I., Burlaka, B., Puzyrenko, A., Ryzhenko, O., Kurochkin, M., Yusuf, J. (2019). Management of amnestic and behavioral disorders after ketamine anesthesia. Georgian medical news, 294, 141–145.
Copyright (c) 2020 Volodymyr Maramukha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.